Vasculitic Neuropathy & Autoimmune Axonal Neuropathies
Vasculitic neuropathy results from inflammatory infiltration and destruction of blood vessel walls supplying peripheral nerves, leading to ischemic nerve damage. It can occur as a manifestation of primary systemic vasculitis, secondary to connective tissue diseases or infections, or as an isolated process limited to peripheral nerves (nonsystemic vasculitic neuropathy). Recognition is critical because immunotherapy can reverse deficits or halt progression, and associated systemic diseases require coordinated multidisciplinary management.
Bottom Line
- Classic presentation: Mononeuritis multiplex — acute to subacute onset of painful, asymmetric, multifocal sensorimotor deficits; later in disease, overlapping mononeuropathies may mimic a symmetric polyneuropathy
- Classification (PNS 2010): Primary systemic vasculitides (small/medium/large vessel), secondary vasculitides (connective tissue disease, infection, drugs), and nonsystemic vasculitic neuropathy (NSVN)
- Key associations: EGPA (asthma + eosinophilia + MPO-ANCA), MPA (renal/pulmonary + MPO-ANCA), GPA (respiratory + PR3-ANCA), PAN (medium vessel, ANCA-negative, hepatitis B link)
- Diagnostic cornerstone: Nerve biopsy of a clinically affected nerve; combined nerve-muscle biopsy improves yield by 27%; ANCA testing (MPO/PR3) is essential for systemic vasculitis classification
- Treatment: 2021 ACR/VF guidelines recommend glucocorticoids plus rituximab for induction in severe ANCA-associated vasculitis; cyclophosphamide is an alternative; maintenance with rituximab, azathioprine, or methotrexate
- Paraneoplastic neuropathies: Subacute, asymmetric axonal neuropathies associated with ANNA-1 (anti-Hu), CRMP-5, and amphiphysin antibodies; most commonly linked to small cell lung cancer
- Prognosis: 35% of ANCA-associated vasculitic neuropathy patients achieve complete resolution within 6 months of treatment; NSVN generally carries a better prognosis than systemic vasculitic neuropathy
Classification of Vasculitic Neuropathy
The Peripheral Nerve Society (PNS) published comprehensive classification guidelines in 2010, dividing vasculitides associated with neuropathy into three major categories. The 2012 Chapel Hill consensus further refined nomenclature with greater emphasis on pathologic findings.
| Category | Subtypes |
|---|---|
| I. Primary systemic vasculitides | |
| Small vessel | Microscopic polyangiitis (MPA), Eosinophilic granulomatosis with polyangiitis (EGPA), Granulomatosis with polyangiitis (GPA), Essential mixed cryoglobulinemia, Henoch-Schönlein purpura |
| Medium vessel | Polyarteritis nodosa (PAN) |
| Large vessel | Giant cell arteritis |
| II. Secondary systemic vasculitides | Connective tissue diseases (RA, SLE, Sjögren, systemic sclerosis, dermatomyositis), sarcoidosis, Behçet disease, infections (HBV, HCV, HIV, CMV, Lyme), drugs, malignancy, IBD |
| III. Nonsystemic/localized vasculitis | Nonsystemic vasculitic neuropathy (NSVN), diabetic radiculoplexus neuropathy, nondiabetic radiculoplexus neuropathy, localized cutaneous vasculitis |
Clinical Presentation
The hallmark of vasculitic neuropathy is mononeuritis multiplex — the sequential or simultaneous involvement of multiple individual nerves in a noncontiguous distribution. Peripheral neuropathy is the presenting symptom in approximately 25% of primary systemic vasculitis cases, particularly in EGPA and PAN.
Cardinal Clinical Features
- Onset: Acute to subacute, often over days to weeks
- Pain: Prominent neuropathic pain, frequently the earliest symptom
- Distribution: Multifocal, asymmetric; upper limb predominance and non-length-dependent features raise suspicion
- Motor and sensory: Mixed sensorimotor involvement with profound sensory loss; pseudoathetosis may occur with severe proprioceptive loss
- Progression: Stepwise worsening as additional nerves are sequentially affected
- Late presentation: Overlapping mononeuropathies may coalesce into an apparently symmetric length-dependent pattern, though some asymmetry usually persists on careful examination or electrophysiology
Red Flags for Vasculitic Neuropathy
- Subacute onset of painful, asymmetric, multifocal neuropathy — especially with constitutional symptoms (fevers, night sweats, weight loss)
- Stepwise progression with new nerve territory involvement
- Non-length-dependent sensory loss or upper limb predominance
- Associated rash (palpable purpura, livedo reticularis), arthritis, renal dysfunction, or pulmonary disease
- New-onset asthma with peripheral eosinophilia — consider EGPA
- Mononeuritis multiplex in a patient with hepatitis B — consider PAN
Primary Systemic Vasculitides With Neuropathy
| Vasculitis | Vessel Size | Neuropathy Frequency | ANCA Association | Key Features |
|---|---|---|---|---|
| MPA | Small | ~50% | MPO-pANCA (most common) | Renal (necrotizing GN with crescents), pulmonary, palpable purpura; no granulomas |
| GPA | Small–medium | ~25% | PR3-cANCA (80%) | Upper/lower respiratory involvement; neuropathy develops later and is milder |
| EGPA | Small–medium | 46–60% | MPO-pANCA; many ANCA-negative | Adult-onset asthma (up to 91%); peripheral eosinophilia; neuropathy may be presenting symptom |
| PAN | Medium | ~50% | ANCA-negative | Renal artery aneurysms, livedo reticularis, cutaneous necrosis; hepatitis B association with higher neuropathy rate |
ANCA-Associated Vasculitides
ANCA testing is of particular importance. Cytoplasmic ANCA (cANCA) targets proteinase 3 (PR3) and is strongly associated with GPA. Perinuclear ANCA (pANCA) targets myeloperoxidase (MPO) and is most commonly associated with MPA and EGPA. In EGPA, MPO-ANCA-positive patients are more likely to have vasculitis on nerve biopsy, whereas MPO-ANCA-negative patients may show more eosinophilic infiltration of blood vessel lumens. Treatment outcomes may differ by ANCA type: one study showed that patients with PR3-ANCA-associated vasculitis were more likely to achieve complete remission at 6 months with rituximab than with cyclophosphamide followed by azathioprine maintenance.
Case Vignette: EGPA With Vasculitic Neuropathy
A 42-year-old woman developed pain and numbness on the dorsum of her left forearm with associated wrist and finger drop over 3 days. One month later, she developed right-sided footdrop with pain and numbness along the outer calf. She had been diagnosed with adult-onset asthma 2 years prior. Laboratory testing revealed MPO-ANCA positivity and peripheral eosinophilia. NCS/EMG confirmed right peroneal and left radial neuropathies without conduction block. Superficial peroneal nerve biopsy showed lymphocytic infiltration and destruction of vessel walls, multifocal nerve fiber loss, and hemosiderin deposition. She was diagnosed with EGPA, and treatment with corticosteroids and rituximab was initiated in coordination with rheumatology.
Key teaching points: The triad of asthma, MPO-ANCA positivity, and eosinophilia with an asymmetric axonal neuropathic process is classic for EGPA. Coordination with rheumatology for systemic vasculitis management is essential.
Cryoglobulinemic Neuropathy
Cryoglobulinemia is a form of vasculitis caused by circulating immunoglobulins that precipitate at low temperatures and deposit in blood vessel walls, initiating complement-dependent vascular damage. It is strongly associated with chronic hepatitis C virus infection — one study demonstrated mixed cryoglobulins in 56% of patients with HCV. Neuropathy in cryoglobulinemia typically presents as a painful, distal, symmetric sensorimotor polyneuropathy or mononeuritis multiplex.
Secondary Vasculitic Neuropathies
Connective Tissue Diseases
Several connective tissue diseases are associated with vasculitic neuropathy, either through direct vasculitic mechanisms or secondary structural effects.
Sjögren syndrome: Between 5% and 20% of patients develop peripheral nervous system complications. The most characteristic neuropathy is sensory neuronopathy (ganglionopathy) with severe proprioceptive loss and sensory ataxia. Other phenotypes include sensorimotor neuropathy, painful small fiber neuropathy, multiple mononeuropathy, and autonomic dysfunction. Nerve biopsy in the mononeuropathy multiplex phenotype frequently shows vasculitis. Treatment responsiveness is variable and generally poor for sensory neuronopathy, though early aggressive treatment within 2 months of onset may improve outcomes. Rituximab shows a 90% neurologic response rate in patients with associated cryoglobulins or vasculitis, but only 29% in those without.
Rheumatoid arthritis (RA): Peripheral nervous system manifestations include entrapment mononeuropathies (most common), cervical myelopathy from atlantoaxial disease, and immune-mediated sensorimotor neuropathy. Up to 57% of RA patients show electrophysiologic evidence of neuropathy, though most are subclinical. Rheumatoid vasculitis, though decreasing in incidence with modern therapy, carries a poor prognosis. TNF-alpha inhibitor therapy for RA can itself trigger neuropathy (often demyelinating), which must be considered as a potential cause.
Systemic lupus erythematosus (SLE): Approximately 13.5% of SLE patients have peripheral nervous system involvement, most commonly an axonal sensory or sensorimotor polyneuropathy. Mononeuritis multiplex occurs in about 9% of affected patients. A good treatment response is more common when polyneuropathy develops early in the SLE course (within the first year).
Nonsystemic Vasculitic Neuropathy (NSVN)
NSVN is vasculitis limited to peripheral nerves without systemic organ involvement. Like systemic vasculitic neuropathy, it can present with stepwise progression and multifocal deficits but may appear symmetric as affected nerve territories coalesce. Asymmetry can often be detected clinically or electrophysiologically, particularly early in the disease course.
Key Features of NSVN
- Definition: Vasculitis confined to peripheral nerves; no evidence of systemic vasculitis on thorough evaluation
- Presentation: Painful, asymmetric or multifocal neuropathy; may appear symmetric in advanced disease
- Diagnosis: Requires nerve biopsy showing vasculitis AND exclusion of systemic vasculitis through comprehensive lab workup and organ screening
- Subtypes include: Nondiabetic radiculoplexus neuropathy (usually monophasic with gradual, sometimes incomplete recovery) and some cases of Wartenberg migratory sensory neuritis
- Prognosis: Generally better than systemic vasculitic neuropathy; some forms are monophasic
- Periodic reassessment: Patients initially diagnosed with NSVN require ongoing surveillance for emergence of systemic disease
Radiculoplexus Neuropathies
The radiculoplexus neuropathies are vasculitic neuropathies limited to nerves with a generally better prognosis than other immune-mediated axonal neuropathies. Diabetic lumbosacral radiculoplexus neuropathy (also called diabetic amyotrophy) is uncommon but severe. A nondiabetic form exists with similar clinical, electrophysiologic, and pathologic findings of microvasculitis. Recovery is often incomplete in both forms. Significant weight loss is commonly associated with radiculoplexus neuropathy.
Diagnostic Evaluation
Laboratory Workup
| Category | Tests |
|---|---|
| Basic | CBC with differential, CMP, ESR, CRP |
| Autoimmune | ANA, anti-ENA antibodies, ANCA (cANCA/PR3 and pANCA/MPO), RF, anti-CCP, complement levels |
| Cryoglobulins/paraproteins | Cryoglobulins, SPEP with immunofixation |
| Infectious | Hepatitis B and C serologies; HIV, Lyme, and other testing as indicated |
| Organ screening | Urinalysis, chest x-ray (systemic disease screening) |
Electrodiagnostic Studies
Nerve conduction studies (NCS) and EMG are critical for evaluating suspected vasculitic neuropathy. The primary goals are to document multifocal nerve involvement and asymmetry through side-to-side comparisons. The study should be carefully designed to assess clinically affected nerves. Early in the disease, findings show asymmetric axonal loss in multiple individual nerve distributions. Later, a more symmetric length-dependent axonal pattern may emerge, but careful examination often reveals residual asymmetry. A history of stepwise progression should be specifically queried in patients with long-standing disease, as electrophysiology may show only nonspecific length-dependent findings.
Nerve Biopsy
Nerve biopsy remains the gold standard for diagnosing vasculitic neuropathy. The PNS published diagnostic criteria for pathologically definite, probable, and possible vasculitis.
| Diagnostic Category | Pathologic Requirements |
|---|---|
| Definite vasculitis | Inflammatory cells in vessel wall + signs of acute vascular damage (fibrinoid necrosis, endothelial disruption, elastic lamina fragmentation, thrombosis, hemorrhage, leukocytoclasia) OR chronic damage with repair (intimal hyperplasia, medial fibrosis, recanalized thrombus) |
| Probable vasculitis | Definite criteria not met + predominantly axonal changes + perivascular inflammation with vascular damage signs, OR perivascular inflammation + additional predictors (complement/IgM/fibrinogen deposition, hemosiderin, asymmetric fiber loss, active axonal degeneration, muscle biopsy necrosis) |
| Possible vasculitis | Definite/probable not met + predominantly axonal changes + vessel wall inflammation without other definite features, OR vascular damage signs without inflammation |
Nerve Biopsy: Practical Considerations
- Site selection: Must biopsy a clinically and electrophysiologically affected nerve to improve diagnostic yield
- Preferred technique: Whole sural nerve biopsy is preferred over fascicular biopsy for vasculitis — interstitium-residing vessels are more consistently assessable
- Common sites: Sural nerve, superficial peroneal nerve (distal sensory nerves)
- Combined biopsy: Addition of peroneus brevis muscle biopsy improves yield of definite vasculitis diagnosis by 27%
- Proximal biopsy: Fascicular biopsy of proximal nerves reserved for cases where infiltrative processes (lymphoma, sarcoidosis) are seriously considered
- When deferred: Biopsy may be unnecessary when clinical evidence of vasculitis involving other organ systems is already established
Neuroimaging
MRI of affected nerves may be considered, particularly when a single nerve or trunk is involved, mainly to exclude alternative etiologies such as infiltrative processes (lymphoma, direct malignant extension, sarcoidosis). MRI can demonstrate increased T2 signal and nerve enlargement, and is also valuable in related conditions such as postsurgical inflammatory neuropathy and neuralgic amyotrophy, where it may reveal nerve constriction and torsion.
Paraneoplastic Neuropathies
Paraneoplastic neuropathies are autoimmune axonal neuropathies driven by immune responses against tumor antigens that cross-react with nervous system components. The most common presentation is an acute to subacute, asymmetric sensory neuronopathy. In many cases, the neurologic symptoms precede cancer diagnosis.
| Antibody | Primary Cancer | Neuropathy Phenotype | Treatment Response |
|---|---|---|---|
| ANNA-1 (anti-Hu) | Small cell lung cancer (81%) | Sensory or sensorimotor neuropathy; 70% sensory-only clinically; autonomic dysfunction common | Generally poor; no benefit from corticosteroids, IVIg, PLEX, or cyclophosphamide |
| CRMP-5 (anti-CV2) | Small cell lung cancer (75%), thymoma (15%) | Painful, asymmetric polyradiculoneuropathy (65%); gastroparesis; axonal pattern on NCS | IV corticosteroids associated with improvement; neuropathy precedes cancer in 96% |
| Amphiphysin | Breast adenocarcinoma (63%), small cell lung cancer (22%) | Polyradiculoneuropathy or sensory neuronopathy; often coexists with CNS disease (encephalopathy, myelopathy, stiff person syndrome) | Immunotherapy significantly associated with improvement; cyclophosphamide + methylprednisolone or IVIg beneficial |
Case Vignette: Paraneoplastic Sensory Neuronopathy (ANNA-1)
A 55-year-old woman with cirrhosis (HCV) and prior tobacco use developed acute patchy right chest and upper extremity pain followed by numbness in the same distribution, then progressive bilateral upper and lower extremity numbness with gait instability requiring wheelchair use within months. She also reported chronic lightheadedness. Chest x-ray revealed a lung nodule, confirmed as adenocarcinoma. Clinical examination showed severe large fiber sensory loss, ataxic gait, and pseudoathetosis with absent reflexes. NCS/EMG confirmed sensory-predominant axonal neuropathy. Autonomic testing revealed postganglionic sympathetic sudomotor dysfunction and moderate orthostatic hypotension. Paraneoplastic panel was positive for ANNA-1 antibodies.
Key teaching points: ANNA-1-associated neuropathy is typically sensory-predominant and severe. Paraneoplastic evaluation should be considered in subacute, progressive, asymmetric neuropathies even when alternative causes are present. Cancer screening must be thorough, as 17% of patients in large series had more than one neoplasm.
Less Common Paraneoplastic Antibodies
| Antibody | Cancer Association | Key Features |
|---|---|---|
| MAP1B-IgG | Lung cancer (usually) | Peripheral neuropathy in 53%; painless polyradiculoneuropathy; 50% respond to immunotherapy |
| LGI1 | Thymoma (more common if double-positive with CASPR2) | Autoimmune encephalitis, neuropathic pain, neuromyotonia; serum more sensitive than CSF; usually responsive to immunotherapy |
| CASPR2 | Thymoma and other cancers (minority) | Limbic encephalitis, neuromyotonia, neuropathic pain |
| NIF (neuronal intermediate filament) | Neuroendocrine carcinoma (~75%) | Ataxia, encephalopathy, myeloradiculoneuropathy; 77% immunotherapy-responsive |
| LUZP4 | Seminoma (vast majority) | Rhomboencephalitis, motor neuronopathy, polyradiculopathy; better outcomes with combined immunotherapy + cancer treatment |
Other Autoimmune Axonal Neuropathies
Postsurgical Inflammatory Neuropathy
A subset of patients develop inflammatory neuropathy following surgery, distinct from positioning-related compression or stretch injury. Clinical clues include a delay between surgery and symptom onset, and progressive symptoms in the days following surgery (median onset 2 days, range up to 30 days). The most common pattern is lumbosacral radiculoplexus neuropathy. NCS/EMG shows an axonal process; CSF protein is elevated in two-thirds. Nerve biopsy demonstrates epineurial perivascular inflammatory collections in all cases, with features of microvasculitis in 15 of 21 cases in one series. Long-term follow-up shows significant improvement regardless of immunotherapy.
Neuralgic Amyotrophy (Parsonage-Turner Syndrome)
Neuralgic amyotrophy presents with acute unilateral shoulder pain resolving within weeks, followed by weakness and sensory deficits. The upper trunk of the brachial plexus, suprascapular, long thoracic, and axillary nerves are most commonly affected. Risk factors include recent viral illness, vaccination, or surgery. MRI and ultrasonography can demonstrate nerve constriction and torsion. Full functional recovery occurs in 89% at 3 years. Treatment is controversial given the monophasic nature; peripheral nerve surgical exploration may be considered after 3 months of conservative management for cases with hourglass constrictions. In patients with recurrent episodes, hereditary brachial plexus neuropathy (SEPTIN9 mutation) should be considered.
Wartenberg Migratory Sensory Neuritis
This rare condition is characterized by rapid-onset sensory symptoms (pain and/or numbness) confined to cutaneous nerve distributions, with a recurrent pattern. Pain in a specific nerve distribution elicited by stretch of the nerve is a frequently noted feature. Long-term follow-up shows a relatively benign course: after a mean disease duration of 7.5 years, most patients had resolution of symptoms or only residual numbness.
Treatment
Systemic Vasculitic Neuropathy
Treatment of systemic vasculitic neuropathy is generally directed by rheumatologists given the multisystem involvement. The 2021 American College of Rheumatology/Vasculitis Foundation guidelines provide the current treatment framework. Mononeuritis multiplex qualifies as organ-threatening disease and is classified as severe by definition.
| Phase | ANCA-Associated (GPA/MPA) | EGPA | PAN |
|---|---|---|---|
| Induction (severe) | Glucocorticoids + rituximab (preferred) or cyclophosphamide | Glucocorticoids (oral or IV) + rituximab or cyclophosphamide | Corticosteroids + cyclophosphamide; antivirals for HBV-associated PAN |
| Maintenance | Rituximab (conditionally recommended); azathioprine or methotrexate as alternatives (equally effective); mycophenolate only if others are not tolerated (higher relapse rate) | Methotrexate, azathioprine, or mycophenolate; rituximab if remission achieved with rituximab or contraindications to other agents | Case-by-case basis |
| Glucocorticoid duration | Case-by-case basis | Case-by-case basis | Case-by-case basis |
NSVN and Localized Forms
Treatment of NSVN follows similar principles to systemic vasculitic neuropathy but may be less aggressive given the absence of systemic organ involvement. Some localized forms (nondiabetic radiculoplexus neuropathy, neuralgic amyotrophy) are monophasic and may improve without immunotherapy, though a course of corticosteroids is often attempted.
Connective Tissue Disease-Associated Neuropathy
Treatment is generally coordinated with rheumatology for the primary disease. For mild neuropathy with predominant pain, symptomatic therapy with neuropathic pain agents may suffice. For severe or progressive cases, immunotherapy is indicated. In SLE-associated polyneuropathy, 89% of patients treated with glucocorticoids and immunosuppressive agents achieved complete or partial remission at 5-year follow-up.
Treatment Pitfalls
- ANNA-1 neuropathy: Generally unresponsive to immunotherapy (corticosteroids, IVIg, PLEX, cyclophosphamide); treatment of the underlying malignancy is paramount
- Sjögren sensory neuronopathy: Treatment window may be as short as 2 months for improvement; beyond 8 months, only stabilization may be achievable
- TNF-alpha inhibitors: Can paradoxically trigger neuropathy (often demyelinating) in RA patients — must be considered as a cause in any RA patient developing neuropathy on biologic therapy
- Mycophenolate for ANCA vasculitis maintenance: Higher relapse rate than azathioprine; should only be used when azathioprine, methotrexate, and rituximab are not options
- Hepatitis-associated vasculitis: HBV-associated PAN requires antiviral therapy; HCV-associated cryoglobulinemia requires antiviral treatment as the foundation
Prognosis
Treatment outcomes in vasculitic neuropathy depend on the underlying cause, timing of diagnosis, and promptness of immunotherapy. One study of 40 patients with ANCA-associated vasculitic neuropathy found that 35% achieved complete resolution within 6 months and all had remission from active neuropathy within 9 months. NSVN and monophasic forms (radiculoplexus neuropathy, neuralgic amyotrophy) generally carry a better prognosis, though recovery is often incomplete. Paraneoplastic neuropathies, particularly ANNA-1-associated, have the poorest neurologic prognosis, with treatment of the underlying malignancy being the primary intervention.
References
- Collins MP, Dyck PJB, Gronseth GS, et al. Peripheral Nerve Society guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst. 2010;15(3):176-184.
- Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1-11.
- Wolf J, Schmitt V, Palm F, Grau AJ, Bergner R. Peripheral neuropathy as initial manifestation of primary systemic vasculitides. J Neurol. 2013;260(4):1061-1070.
- Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383.
- Vital C, Vital A, Canron MH, et al. Combined nerve and muscle biopsy in the diagnosis of vasculitic neuropathy: a 16-year retrospective study of 202 cases. J Peripher Nerv Syst. 2006;11(1):20-29.
- Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270-281.
- Nishi R, Koike H, Ohyama K, et al. Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology. 2020;94(16):e1726-e1737.
- Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa. Arthritis Rheum. 2010;62(2):616-626.
- Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. Medicine (Baltimore). 2000;79(1):47-56.
- Suppiah R, Hadden RDM, Batra R, et al. Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology. 2011;50(12):2214-2222.
- Unizony S, Villarreal M, Miloslavsky EM, et al. Clinical outcomes of treatment of ANCA-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75(6):1166-1169.
- Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. Brain. 2005;128(Pt 11):2518-2534.
- Pereira PR, Viala K, Maisonobe T, et al. Sjogren sensory neuronopathy (Sjogren ganglionopathy): long-term outcome and treatment response in a series of 13 cases. Medicine (Baltimore). 2016;95(19):e3632.
- Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71(1):84-87.
- Agarwal V, Singh R, Wiclaf, et al. A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis. Clin Rheumatol. 2008;27(7):841-846.
- Ntatsaki E, Mooney J, Scott DGI, Watts RA. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology. 2014;53(1):145-152.
- Florica B, Aghdassi E, Su J, et al. Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2011;41(2):203-211.
- Fargetti S, Ugolini-Lopes MR, Pasoto SG, et al. Short- and long-term outcome of systemic lupus erythematosus peripheral neuropathy. J Clin Rheumatol. 2021;27(6S):S212-S216.
- Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998;50(3):652-657.
- Camdessanche JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. Brain. 2002;125(Pt 1):166-175.
- Dubey D, Lennon VA, Gadoth A, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 2018;90(2):e103-e110.
- Dubey D, Jitprapaikulsan J, Bi H, et al. Amphiphysin-IgG autoimmune neuropathy: a recognizable clinicopathologic syndrome. Neurology. 2019;93(20):e1873-e1880.
- Staff NP, Engelstad J, Klein CJ, et al. Post-surgical inflammatory neuropathy. Brain. 2010;133(10):2866-2880.
- Gstoettner C, Mayer JA, Rassam S, et al. Neuralgic amyotrophy: a paradigm shift in diagnosis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):879-888.
- Dyck PJB, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve. 2002;25(4):477-491.